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Abstract
Introduction:	 In	 Prader–Willi	 syndrome	 (PWS),	 nonprotein	 coding	 small	 nucleolar	
(sno)	RNAs	are	 involved	 in	the	paternally	deleted	region	of	chromosome	15q11.2‐
q13,	which	is	believed	to	cause	the	hyperphagic	phenotype	of	PWS.	Central	to	this	is	
SnoRNA116. The supplement Caralluma fimbriata extract (CFE) has been shown to 
decrease appetite behavior in some individuals with PWS. We therefore investigated 
the mechanism underpinning the effect of CFE on food intake in the Snord116del 
mouse.	 Experiments	 utilized	 appetite	 stimulants	 which	 included	 a	 5‐hydroxy‐
tryptamine	(5‐HT)	2c	receptor	antagonist	(SB242084),	as	the	5‐HT2cR	is	implicated	
in central signaling of satiety.
Methods:	After	9‐week	chronic	CFE	treatment	(33	mg	or	100	mg	kg−1 day−1) or pla‐
cebo,	the	14‐week‐old	Snord116del (SNO)	and	wild‐type	mice	(n = 72) were rotated 
through	intraperitoneal	injections	of	(a)	isotonic	saline;	(b)	400	mg/kg	of	2‐deoxyglu‐
cose	 (2DG)	 (glucose	 deprivation);	 (c)	 100	mglkg	 beta‐mercaptoacetate	 (MA),	 fatty	
acid	 signaling;	 and	 (d)	 SB242084	 (a	 selective	5HT2cR	antagonist),	with	5	days	be‐
tween	reagents.	Assessments	of	food	intake	were	from	baseline	to	4	hr,	followed	by	
immunohistochemistry	of	neural	activity	utilizing	c‐Fos,	neuropeptide	Y,	and	alpha‐
melanocyte‐stimulating	hormone	within	hypothalamic	appetite	pathways.
Results: Caralluma fimbriata extract administration decreased food intake more 
strongly in the SNO100CFE group with significantly stimulated food intake demon‐
strated during coadministration with SB242084. Though stimulatory deprivation was 
expected	to	stimulate	food	intake,	2DG	and	MA	resulted	in	lower	intake	in	the	snord‐
116del mice compared to the WT animals (p = <0.001). Immunohistochemical map‐
ping of hypothalamic neural activity was consistent with the behavioral studies.
Conclusions:	This	study	 identifies	a	 role	 for	 the	5‐HT2cR	 in	CFE‐induced	appetite	
suppression and significant stimulatory feeding disruptions in the snord116del mouse 
model.
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1  | INTRODUC TION
Prader–Willi syndrome (PWS) is a neurogenetic disorder charac‐
terized by neonatal hypotonia and failure to thrive. The syndrome 
follows	 a	 trajectory	 from	 these	 core	 criteria,	 through	 early	 child‐
hood‐onset	obesity	to	establishing	hyperphagia	(excessive	appetite)	
and	repetitive	food‐focussed	behaviors	at	the	mean	age	of	8	years	
(Cassidy	 &	 Driscoll,	 2009;	 McCandless,	 2011).	 Typically,	 PWS	 is	
life‐threatening	without	routine	management	by	dieting	and	super‐
vision.	This	is	mainly	due	to	sleep	apnea,	choking,	stomach	necrosis,	
or	 obesity‐related	 complications	 (Stevenson	et	 al.,	 2007).	 To	date,	
pharmacological treatments for the suppression of appetite in PWS 
have	 shown	minimal	 efficacy	 (Griggs,	 Sinnayah,	 &	Mathai,	 2015);	
however,	interestingly	the	Indian	cactus	succulent	Caralluma fimbri‐
ata (CFE) has demonstrated favorable modulation of hyperphagia 
and appetite behaviors in our clinical pilot study of children and ado‐
lescents with PWS (n	=	15)	(Griggs,	Su,	&	Mathai,	2015).
Clinical	studies	of	CFE’s	efficacy	in	non‐PWS	obese	adults	have	
demonstrated suppression of appetite and reductions of waist cir‐
cumference	(Astell,	Mathai,	McAinch,	Stathis,	&	Su,	2013;	Kuriyan	et	
al.,	2007;	Lawrence	&	Choudhary,	2004).	Studies	in	animals	report	
similar	attenuation	of	 food	 intake,	and	 importantly	comprehensive	
toxicity assessments assure the safety of treatment CFE (Odendaal 
et	 al.,	 2013;	 Sakore,	 Patil,	 &	 Surana,	 2012).	 However,	 character‐
ization of the mechanism of action of CFE remains hypothetical 
(Kamalakkannan,	Rajendran,	Venkatesh,	Clayton,	&	Akbarsha,	2010,	
2011	;	Komarnytsky,	Esposito,	Rathinasabapathy,	Poulev,	&	Raskin,	
2013;	Rajendran	et	al.,	2014).	Observations	 in	animals	 include	 im‐
provements in the lipid profile and reduction in levels of leptin 
and/or	 blood	 glucose	 (Ambadasu,	 Dange,	 &	Wali,	 2013).	 Further,	
in	mouse‐derived	3T3‐L1	cell	lines,	CFE	has	inhibited	preadipocyte	
cell	division	during	adipogenesis	in	a	dose	and	time‐dependent	man‐
ner	 (Kamalakkannan,	 Rajendran,	 Venkatesh,	 Clayton,	 &	 Akbarsha,	
2010). It is proposed that CFE’s mechanism of action involves the 
pregnane	glycosides,	both	as	an	antihyperglycemic	(Priya,	Rajaram,	
&	Sureshkumar,	 2014)	 and	 as	 an	 antinociceptive	 (Rajendran	et	 al.,	
2014) and that the various steroidal glycosides increase stimula‐
tion	of	the	anorexigenic	melanocortin	pathway	(Komarnytsky	et	al.,	
2013). These specific hypothalamic appetite pathways are believed 
to	 be	 disturbed	 due	 to	 genetic	 modifications,	 one	 specifically	 in‐
volved	in	modifying	the	genetic	translation	of	the	5‐HT2c	receptor.
Implicated in the PWS phenotype are five critically deleted pro‐
tein	 coding	 paternal	 genes	 in	 the	 region	 on	 chromosome	 15q11.2‐
q13.1	 (MKRN3, MAGEL2, NECDIN, SNURF‐SNRPN,	 NPAP1/C15orf2) 
and	 six	 nonprotein	 coding	 C/D	 box	 small	 nucleolar	 RNA	 (SnoRNA)	
genes	or	SNORDs:	107,	64,	108,	109,	116,	and	115.	The	proximation	
of	SnoRNAs’	regulation	of	premRNA	splicing	and	methylation	of	tar‐
geted	RNAs	is	not	fully	understood	and	not	able	to	be	approximated	
in	animal	models	as	little	is	known	of	their	functional	consequences.	
However,	at	this	time	the	SNORD116 is noted to be the most likely of 
the	SnoRNA	candidates	pertaining	to	the	severity	of	the	syndrome	in	
humans.	In	mice,	deletion	of	SnoRNA116	influences	serotonin	or	5‐hy‐
droxytryptamine	(5HT)‐mediated	behaviors	and	appetite	modulation	
through	neuropeptide	Y	(NPY)	(Duker	et	al.,	2010;	Falaleeva,	Surface,	
Shen,	 Grange,	 &	 Stamm,	 2015;	 Gallagher,	 Pils,	 Albalwi,	 &	 Francke,	
2002;	McAllister,	Whittington,	&	Holland,	2011;	Qi	et	al.,	2016;	Zieba	
et	al.,	2015)	also	involved	in	homeostatic	processes	with	the	melano‐
cortin pathway. We therefore chose to investigate regulation of food 
intake—due	 to	CFE—in	 the	Garvan	Snord116 deletion mouse model. 
This genetic deletion in the mouse’ chromosome 7C creates a hyper‐
phagic	phenotype	(Duker	et	al.,	2010;	Kantor,	Shemer,	&	Razin,	2006)	
which is relatively homologous with the human PWS paternally de‐
leted	chromosome	15.	However,	the	animal	does	not	become	obese	
as is the case with all mouse models replicating genetic deletions from 
the	PWS	critical	region	(Bervini	&	Herzog,	2013;	Golding,	et	al.,	2017).
We hypothesized that CFE steroidal glycosides were involved 
in	 appetite	 suppression	 by	 enhancing	 5‐HT2c	 receptor	 signal‐
ing	 (Canton	 et	 al.,	 1996;	 Doe	 et	 al.,	 2009;	 Falaleeva	 et	 al.,	 2015;	
Schellekens	 et	 al.,	 2015).	 Though	 typically	5‐HT	or	 serotonin	may	
be	 increased	 through	 pharmaceutical	 treatment,	 that	 is,	 selective	
serotonin	reuptake	 inhibition	 (SSRI)	 (Griggs,	Sinnayah,	et	al.,	2015;	
Selikowitz,	Sunman,	&	Wright,	1990);	treatments	of	this	nature	re‐
quire	 active	 5‐HT	 receptors	 to	 release	 second	messenger	 activity	
within the appetite pathways of the central nervous system (CNS). 
The	 literature	 describes	 5‐HT2cR’s	 anorexigenic	 receptor	 activity	
predominantly	within	 the	arcuate	nucleus	 (ARC)	of	 the	hypothala‐
mus	(Reynolds,	Hill,	&	Kirk,	2006).	Moreover,	in	the	ARC	food	intake	
may also be inhibited by plasma leptin increase in proopiomela‐
nocortin	 (POMC)	 neurons	 coexpressing	 5‐HT2cR	 mRNA	 (Khan,	
Gerasimidis,	Edwards,	&	Shaikh,	2016); (Zhou	et	al.,	2005).	These	an‐
orexic	 signals	 further	 release	a	downstream	melanocortin	agonist,	
alpha‐melanocyte‐stimulating	hormone	(α‐MSH),	via	paraventricular	
(PVN)	neural	afferents	of	the	hypothalamus.	This	signaling	pathway	
activates	inhibition	via	the	melanocortin	4	receptor	(MC4R)	(Cone,	
2005;	Cowley,	2003;	Ellacott,	Halatchev,	&	Cone,	2006;	Yosten	&	
Samson,	2010)	as	a	homeostatic	response	to	balance	food	intake	in	
opposition	to	the	orexigenic	NPY	neuronal	pathway.	 It	 is	 reported	
that hyperphagic feeding in the Snord116del mice is due to enhanced 
NPY	activity	(Bervini	&	Herzog,	2013;	Zhang,	Bouma,	McClellan,	&	
Tobet,	2012);	we	therefore	targeted	the	melanocortin	appetite	path‐
way	 (Komarnytsky	 et	 al.,	 2013)	 via	 the	 5‐HT2c	 receptor	 to	 firstly	
determine	homeostatic	balance	with	NPY	(Heisler	et	al.,	2006;	Zhou	
et	al.,	2005)	and	to	discover	whether	CFE	signaling	involved	this	re‐
ceptor.	As	this	receptor	has	been	reported	to	be	disrupted	in	humans	
with	PWS	(Angulo,	Butler,	&	Cataletto,	2015;	Isles,	2017;	Kishore	&	
Stamm,	2006;	Stamm,	Gruber,	Rabchevsky,	&	Emeson,	2017),	it	is	im‐
portant to understand whether CFE’s action involves this pathway. 
The	therefore	utilized	an	appetite	stimulant	5‐HT2cR	antagonist,	(iv)	
SB	242084,	which	was	expected	to	stimulate	feeding	by	inhibiting	
serotonin	transmission	(Kennett	et	al.,	1997); (Lam	et	al.,	2007).
We were also keen to elucidate whether any hunger experienced 
by the Snord116del mouse was due to CFE or due to metabolic alter‐
ations	regarding	carbohydrates,	fatty	acids,	or	malabsorption	of	food.	It	
is well known that ingestion of carbohydrates or dietary fatty acids in‐
creases	blood	levels	of	glucose	or	lipids,	which	in	turn	modify	appetite	
signaling in the hypothalamus. Past research on CFE has demonstrated 
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that pregnane glycosides (the proposed active constituent of CFE) 
alter lipid metabolism and inhibit fatty acid biosynthesis (Selikowitz 
et	al.,	1990).	To	this	end,	we	utilized	acute	stimulation	of	food	intake	
through	administration	of	2‐deoxy‐D‐glucose	(2DG),	which	stimulates	
glucoprivic	 feeding	and	sodium	mercaptoacetate	 (MA),	which	stimu‐
lates lipoprivic feeding through either inhibition of the availability of 
glucose	or	fatty	acids	as	metabolic	fuels	 (Li,	Wiater,	Wang,	Wank,	&	
Ritter,	2016;	Ritter	&	Taylor,	1990).	Administration	of	2DG	or	MA	has	
been utilized to stimulate food intake and determine specific areas of 
neuronal	activation	within	the	brain	in	rodents	(Ritter	&	Taylor,	1990).	
These variables were important to consider when determining if ob‐
served	short‐term	appetite	results	were	associated	with	the	metabolic	
pathway,	treatment,	or	the	mouse	strain.	The	full	first	round	of	stim‐
ulatory experiments was immediately followed by acute stimulatory 
experiments	 with	 2DG	 for	 immunohistochemistry	 investigations	 of	
hypothalamic cell activity within the CNS in the same animals.
2  | METHODS
2.1 | Animals
The Snord116del mouse	strain	homozygote	(Ding	et	al.,	2008)	mating	
pairs	and	wild‐type	(WT)	control	homozygote	mating	pairs	(bred	from	the	
same	original	C57BL/6	laboratory	stock)	(Purtell,	Aepler,	Qi,	Campbell,	
&	 Herzog,	 2017)	 were	 generously	 gifted	 to	 our	 study	 by	 Herbert	
Herzog	of	the	Garvan	Institute.	These	animals	were	transported	to	the	
Florey	Neuroscience	 Institute	 (FNI),	Melbourne,	Australia,	 in	 accord‐
ance	with	 relevant	guidelines	under	ethics	approval	14‐081	FINMH.	
The	strain	was	obtained	with	permission	from	Jackson	Laboratory	(Bar	
Harbor,	ME,	USA)	C57BL/6(Cg)‐Snord116tm1Uta/J;	Stock	No:	008118)	
and	 was	 originally	 bred	 at	 ABR	 (Australian	 Bio‐Resources	 Pty	 ltd.,	
Moss	Vale,	NSW,	Australia).	The	colony	raised	72	mice	(Snord116del/
SNO	×	36	18	male	(M)	&	18	female	(F),	WT	×	36—18	M	and	18F),	bred	
within	7	weeks	of	each	other.	All	mice	stayed	with	their	mothers	until	
weaning	at	4	weeks	of	age.	Due	to	good	numbers	per	litter,	this	study	
was	able	to	utilize	only	first‐generation	animals	from	the	mating	pairs	
for the experimental protocol. No pair had more than two litters within 
the	timeline	and	these	were	then	divided	into	six	groups	of	12,	and	sin‐
gle‐housed	in	standard	conditions	in	a	temperature‐controlled	(21°C)	
mouse	facility	with	a	12‐hr	light:	dark	cycle	(lights	on	0600–1800	hr).	
The	 groups	were	 randomized	 by	weight,	 parentage,	 and	 sex.	At	 the	
time	of	the	experiments,	the	3	×	Snord116del	groups	were	5%	lighter	
on	average,	with	animals’	body	weight	ranging	from	Snord116del/SNO: 
17.6–23.8	g	and	WT:	18.2–25.8	g	at	14	weeks.
2.2 | Treatments
From	6	weeks	of	age,	the	strain	groups	received	basic	chow	and	either	
a daily treatment (dose per weight) of standardized CFE powdered ex‐
tract	(CFE	33	or	100	mg/kg)	or	a	placebo	(PLAC)	(200	mg/kg	malto‐
dextrin	and	50	mg	cabbage	leaf),	a	similarly	mild‐bitter	tasting	powder	
(SNO	×	12/WT	×	12	(Male	(M)	×	6	&	Female	(F)	×	6—CFE100	mg/kg),	
SNO	×	12/WT	×	12	 (M	×	6	 &	 F	×	6—CFE33	mg/kg)	 and	 SNO	×	12/
WT	×	12	 (M	×	6	&	F	×	6—PLAC).	Both	 treatments	were	dissolved	 in	
jelly	and	ingested	over	9	weeks	(wks)	before	acute	stimulation	of	food	
intake	with	(a)	administration	of	 isotonic	saline	(SAL);	 (b)	administra‐
tion	of	2DG;	and	(c)	MA.	To	make	the	jelly	daily,	CFE	and	PLAC	were	
dissolved	 in	 25	ml	 of	water	 and	 added	 to	 125	ml	 of	 gelatine	 (Davis	
Gelatine,	GELITA	Australia	Pty.	Ltd)	(Purtell	et	al.,	2017).	Each	treat‐
ment	contained	2%	saccharin	(0.05	mg	=	2%)	as	a	heat	stable	low‐cal‐
orie	sweetener	that	ensured	voluntary	ingestion.	Visual	confirmation	
of all jelly ingestion was made as well as daily measurements of body 
weight and food intake. Water was provided ad libitum.
2.3 | Appetite stimulation
At	 14	wks	 of	 age	 during	 the	 9th	 week	 of	 administration,	 appetite	
stimulants	were	administered	by	 intraperitoneal	 (i.p)	 injection,	 in	the	
order	a–d,	with	4	to	5‐day	break	between	each	experimental	protocol.	
The	experimental	reagents	were	(a)	SAL—isotonic	saline,	utilized	as	a	
control;	(b)	2DG—2‐deoxyglucose	(400	mg/kg,	Sigma‐Aldrich	2‐deoxy‐
D‐glucose,	D83755G),	 prompting	glucose	deprivation;	 (c)	MA—beta‐
mercaptoacetate	 (100	mg/kg,	 Sigma‐Aldrich,	 methyl	 thioglycolate	
108995‐100G),	stimulating	fatty	acid	signaling,	and	(d)	SB	242084—5‐
HT2cR	antagonist	 (1	mg/kg,	 Sigma‐Aldrich,	 SB	242084	dihydrochlo‐
ride	hydrate,	S8061‐5	mg),	prompting	an	orexigenic	response.
On	the	morning	of	each	protocol	either	a,	b,	c,	or	d,	the	animals’	
weights were recorded for reagent volume and daily treatment CFE 
or	PLAC	was	confirmed	as	 ingested.	The	 timeline	 for	 the	 tests	 in‐
corporated 2 hr of fasting preinjection and 4 hr of observation 
postinjection. Food and water were removed (2 hr) before base‐
line.	At	baseline	 (14.30	p.m.),	all	groups	 (SNO100CFE;	SNO33CFE;	
SNOPLAC	or	WT100CFE;	WT33CFE	 and	WTPLAC)	 received	 that	
day’s	protocol	 reagent	 (SAL;	2DG;	MA	or	SB242084	 in	1	ml	saline	
solution) by i.p. injection at the specified volume for each animal’s 
weight. Measured data involved the amount of basic chow eaten and 
water	consumed	by	each	animal	after	4	hr,	which	included	1	hr	into	
the	dark	cycle,	where	natural	feeding	was	expected.	The	administra‐
tion	of	treatments,	stimulants,	and	measurements	of	food	and	water	
followed	an	identical	ordered	cycle	in	all	72	first‐generation	animals.
2.4 | Immunohistochemistry
At	17	wks	of	age,	after	statistical	analysis	of	the	stimulant	experi‐
ments,	the	mice	ingesting	CFE	at	the	highest	dose	CFE100CFE	or	
PLAC	 (SNO100CFE;	SNOPLAC;	WT100CFE	or	WTPLAC,	n = 48) 
were	 randomly	 allocated	 to	 either	 2DG	 acute	 stimulant	 or	 con‐
trol	 SAL	 groups	 for	 immunohistochemistry	 experimentation.	 At	
90	min,	 eight	 randomly	 chosen	 mice	 per	 day	 were	 weighed	 to	
the nearest 0.1 gram to determine the reagent volume and were 
given	 an	 i.p.	 injection	 of	 SAL	 or	 2DG	 before.	 The	 animals	 were	
then	 timed	 for	 perfusion,	 for	 which	 they	 were	 given	 an	 i.p.	 in‐
jection of sodium pentobarbitone (dose—80 mg/kg). They were 
perfused transcardially by normal saline and paraformaldehyde 
(PFA)	 (4%)	 in	 0.1	M	 phosphate	 buffer	 (PB)	 (pH7.2).	 The	 brains	
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were	 removed	 and	 cryoprotected	 for	 storage	 at	 (20°C)	 until	 im‐
munohistochemistry	processing	by	 immersion	 in	30%	sucrose	by	
weight (w/v) in 0.1 M PB for 72 hr followed by freezing in isopen‐
tane. Immunohistochemistry processes were carried out by the 
Melbourne	Brain	Centre,	Victoria,	Australia.	Free‐floating	coronal	
sections	 of	 40	µm	 thickness	 were	 cut	 on	 a	 Leica	 Microsystems	
CM1850	 cryostat	 relative	 to	 the	 specified	 area	 of	 interest	 (AOI)
from	Bregma	1.10	mm	to	−2.92	mm	(striatum,	hypothalamus,	mid‐
brain)	of	the	mouse	brain:	a)	ARC:	arcuate	nucleus	of	the	hypothal‐
amus	 b)	 PVN:	 paraventricular	 nucleus	 of	 the	 hypothalamus.	 The	
sections	were	placed	 into	cryoprotectant	solution	 (30%	ethylene	
glycol	and	15%	sucrose	in	PB)	and	stored	at	−20°C	prior	to	staining.
2.5 | Triple labeled Immunofluorescence
Primary	 antibodies	 were	 diluted	 in	 antibody	 diluent	 (1%	 normal	
donkey	serum	 (NDS)	and	1%	Triton	X‐100	 in	PB)	as	 follows:	 rabbit	
anti‐c‐Fos	primary	1:2000,	anti‐NPY	1:1,000,	(Abcam,	anti‐NPY	an‐
tibody:	ab112473	NPY,	mouse	monoclonal)	and	anti‐MSH	1:10,000	
(Merc‐Millipore,	 anti‐MSH	 α‐antibody).	 Sections	 were	 incubated	
with	 primary	 antibodies	 over	 two	 nights	 at	 4°C	 with	 agitation.	
Before	staining,	the	sliced	sections	were	washed	in	PB	(2	×	10	min)	
and were blocked for 30 min at room temperature with agitation 
in	10%	NDS	and	1%	Triton	X‐100	(Sigma‐Aldrich)	 in	PB.	Secondary	
antibodies	were	diluted	 in	 antibody	diluent	 at	1:400	NPY—donkey	
anti‐mouse/rabbit	 488	 (green)	 (Alexa	 Fluor®	 488	 AffiniPure	 don‐
key	 anti‐mouse)	 IgG	 (H	+	L)	 (Luo	et	 al.,	 2015),	 and	α‐MSH:	donkey	
anti‐rabbit	 IgG	(H	+	L),	secondary	antibody	(red)	 (Alexa	Fluor®	594	
conjugate	a21207)	(Zhang,	2011),	and	c‐Fos	donkey	anti‐sheep	647	
(purple)	(Alexa	Fluor®	647)	(Purkartova	et	al.,	2014).	Sections	were	
incubated with secondary antibodies (3 hr) at room temperature. 
Sections were washed and mounted on Superfrost Plus slides (Hurst 
Scientific) in mounting medium. Images of the mouse brain sections 
were	 obtained	 at	 40X	magnification	 using	 a	Nikon	 E400	 confocal	
microscope.
2.6 | Statistical analysis
Results	were	analyzed	using	SPSS	version	23.0	for	Windows.	All	data	
were determined as normally distributed with p ≤ 0.05	as	significant.	
Analysis	of	food	intake,	thirst	(not	shown),	and	totals	of	c‐Fos	labeled	
neurons were organized into mean ± SD per group. The results in‐
volved food ingested by strain × 2; treatment × 3; and stimulant × 4 
in groups (n	=	12).	Effect	sizes	were	analyzed	by	two‐way	MANOVA	
for	significance,	followed	by	a	repeated‐measures	ANOVA	for	uni‐
variate	measures,	with	Bonferroni	corrections	for	multiple	compari‐
sons. This determined the significance of the reagents against both 
strain	and	treatment	as	between‐group	factors	of	variance.	ANOVAs	
were followed by unpaired t tests analyzing stimulating reagents 
against	SAL	control	for	within	group	factors	of	variance.
Labeled	 cell	 numbers	 were	 analyzed	 by	 a	 two‐way	 ANOVA.	
Normality with no missing values was met in the groups (n	=	5),	with	
two dependent variables of strain (Snord116del/SNO	 and	WT),	 two	
dependent	variables	of	treatment	(100	CFE/kg/day	&	PLAC),	and	two	
dependent	variables	of	stimulation	(SAL	and	2DG).	There	were	three	
independent	 variables	 of	 labeled	 channel	 activity,	 FITC	 (488):	 NPY;	
AL	×	594	(561):	α‐MSH	and	Cy5	(640):	c‐Fos	×	2‐3	slides	per	AOI.	The	
results	were	defined	with	strain,	treatment,	and	stimulation	as	factors	
of	 variance.	This	was	 followed	by	post	hoc,	Tukey’s	 tests	 to	 specifi‐
cally pinpoint significance related to the eight group variations (n	=	5	
mice	×	8	 groups:	 ARC	×	2‐3	 sections	 per	mouse,	 PVN	×	2‐3	 sections	
per mouse); per image (n	×	7;	c‐Fos;	NPY/c‐Fos;	α‐MSH/c‐Fos;	NPY/α‐
MSH;	and	NPY/α‐MSH/c‐Fos).
3  | RESULTS
3.1 | Appetite stimulation
The stimulation results determined complex significant differences 
in	 food	 intake	due	 to	 treatments,	 stimulants,	 and	 strain.	 The	 low‐
est food intake recorded over the 4 hr within Snord116del animals 
was	in	the	100CFE	group	during	2DG	stimulation	(Table	1)	and	for	
the	WT	strain,	during	MA	stimulation	in	the	100CFE	animals.	Under	
SAL	control	conditions,	the	Snord116del strain demonstrated hyper‐
phagia,	eating	more	than	the	WT	animals:	Snord116del/SNO (n	=	36)	
1.39	±	0.32	g;	WT	 (n	=	36)	 0.89	±	0.32	g	 (p = 0.007). Though their 
food	 intake	was	higher,	 there	was	 still	 a	 small	 significant	dose	 re‐
sponse	in	reduced	food	intake	due	to	CFE’s	dose,	SNO100CFE	ani‐
mals,	against	the	lower	dose	33CFE,	SAL—SNO100CFE	1.27	±	0.27	g;	
SNO33CFE 1.47 ± 0.23 g (p = 0.03). In comparison under basal 
conditions,	 the	 WT	 mice	 demonstrated	 no	 significant	 alterations	
between	 the	 treatment	 groups	 SAL—WT100CFE	 0.81	±	0.27	g;	
WT33CFE	0.94	±	0.30	g	(NS,	p = 0.32).
Unusually even though the snord116 deletion caused hyperpha‐
gia;	during	the	acute	stimulation	tests,	the	Snord116del mice experi‐
enced significant inhibitions of food intake.
Within strain comparisons of glucoprivic and lipoprivic food intake 
demonstrated	that	though	i.p	injections	of	2DG	stimulated	feeding	
in	the	WT	animals,	2DG	did	not	stimulate	feeding	in	the	Snord116del 
mice	 (Table	 1),	 2DG:	 SNO100CFE	 0.78	±	0.37	g;	 WT100CFE	
1.19	±	0.18	g,	 (p = 0.002);	 SNO33CFE	 0.98	±	0.29	g;	 WT33CFE	
1.36	±	0.30	g	 (p =	<0.001);	 and	 2DG:—SNOPLAC	 1.01	±	0.26	g;	
WTPLAC	 1.56	±	0.67	g	 (p = 0.01).	 In	 fact,	 the	 Snord116del strains 
food intake were indicative of signaling disruptions with significant 
inhibition	 of	 food	 intake	 in	 response	 to	 2DG,	 SAL—SNO100CFE	
1.27	±	0.27	g	 in	 comparison	with	2DG—SNO100CFE	0.78	±	0.37	g	
(p = 0.002);	 SAL—SNO33CFE	 1.47	±	0.23	g;	 2DG—SNO33CFE	
0.98	±	0.29	g	 (p =	<0.001).	 Further,	 the	 results	 suggested	 this	 in‐
hibited stimulation was due to the Snord116 deletion and not treat‐
ment with CFE as reduced food intake in the Snord116del strain 
during	 glucose	 deprivation	was	 similar	 in	 the	 PLAC	 group,	 2DG—
SNOPLAC	1.01	±	0.26	g;	SAL—SNOPLAC	1.46	±	0.41	g	 (p = 0.003). 
In	the	WT	strain	under	2DG	stimulated	deprivation	treatment,	CFE	
only	resulted	in	a	trend	in	lessening	food	intake	2DG:—WT100CFE	
1.19	±	0.18	g;	WT33CFE	1.36	±	0.30	g;	WTPLAC	1.56	±	0.67	g	(NS,	
p = 0.08).
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MA’s	 stimulatory	 effect	 was	 minimal	 in	 all	 groups	 though	
there were also some unexpected strain comparisons (Table 1 and 
Figure	1).	Once	again	unexpectedly,	stimulation	inhibited	food	in‐
take in the Snord116del	strain.	MA	fatty	acid	deprivation	resulted	
in significant differences between strain’s treatment groups 
(Table 1).
The major significant interactions within strains in food intake 
were	during	 administration	of	 the	5HT2c	 receptor	 antagonist	 SB	
242084.	A	higher	food	intake	was	measured	in	animals	that	had	in‐
gested	CFE	over	the	prior	9	weeks,	as	compared	to	PLAC.	The	WT	
animals demonstrated significant differences in food intake espe‐
cially	due	to	administration	of	CFE,	SAL—WT100CFE	0.81	±	0.27;	
SB	242084	WT100CFE	1.61	g	±	0.61	g	(p	≤	0.001),	SAL,	WT33CFE	
0.94	±	0.30;	SB	242084	WT33CFE	1.79	g	±	0.70	g	(p≤	0.001).	The	
PLAC	 group	 demonstrated	 less	 increase	 in	 food	 intake	 (NS).	 The	
strongest increase in food intake within the Snord116del strain 
was	in	the	SNO100CFE	due	to	SB	242084	antagonism.	However,	
this result was not significant as the Snord116del strain also ex‐
hibited	hyperphagia	under	 control	 conditions,	 SAL:—SNO100CFE	
1.27	±	0.27	g;	 SB	 242084	 SNO100CFE	 1.46	g	±	0.38	g	 (NS,	
p = 0.11).
Over	 all	 experiments,	 the	 most	 significant	 difference	 in	 food	
intake was seen in the WT animals during SB 242084 antagonist 
administration,	SAL—WT33CFE	0.94	±	0.30;	SB	242084	WT33CFE	
1.79	g	±	0.70	g	 (p ≤	0.001)	 (Table	 1).	 The	 5‐HT2cR	 antagonist	 SB	
242084 was the most powerful stimulant in both strains and all 
treatment	groups.	SB	242084	enhanced	the	feeding	for	all	groups,	
including	the	PLAC	groups.	These	experiments	suggest	the	5‐HT2c	
receptor is involved in the mechanistic activity of CFE. In the WT 
animals,	food	intake	was	significantly	increased	in	the	100CFE	and	
33CFE	treatment	groups,	compared	to	the	PLAC	group,	SB	242084—
WT100CFE	1.61	g	±	0.61	g;	WTPLAC	1.25	g	±	0.44	g	(p = 0.02),	and	
SB	 242084—WT33CFE	 1.79	g	±	0.70	g,	 WTPLAC	 1.25	g	±	0.44	g	
(p = 0.04).
3.2 | Immunohistochemistry
In	the	ARC,	there	was	a	significant	difference	in	NPY	and	c‐Fos	dual‐
labeled	neurones	between	strains	 in	 response	 to	2DG	stimulation,	
NPY—SNOPLAC	21.0	±	15.93;	WTPLAC	159.8	±	65.53	 (p = <0.001) 
(Figure	2).	These	 results	were	 supported	by	coexpression	of	 c‐Fos	
and	 NPY	 in	 the	 PVN,	 which	 demonstrated	 significant	 differences	
between	 the	 strains	 in	 response	 to	 2DG—SNOPLAC	51.0	±	15.84;	
WTPLAC	138.2	±	49.17	 (p = 0.005)	 and	 the	2DG	NPY—SNO‐PLAC	
24.0	±	12.94;	WT‐PLAC	76	±	18.07	(p = <0.001). Comparisons of ac‐
tivity through α‐MSH	and	c‐Fos	dual‐labeled	neurones	indicated	the	
significant differences between strains. The highest WT satiety sign‐
aling	activity,	due	to	treatment	CFE,	was	in	the	ARC	of	the	control	
SAL—WT100CFE	and	in	the	Snord116del	strain	was	due	to	2DG	stim‐
ulation,	2DG—SNO100CFE	 (Figure	3	and	Table	2).	The	SNOPLAC‐
SAL	controls	had	the	lowest	α‐MSH	colocalization	to	c‐Fos	(Table	2).
4  | DISCUSSION
CFE	 administration	 induced	 strain‐specific	 differences	 in	 food	
intake in response to acute stimuli. In the Snord116del	 mice,	 the	
lowest food intake was in the SNO100CFE group under all condi‐
tions (Table 1). There were also significant differences between the 
treatment	groups	 in	the	WT	strain	due	to	CFE,	during	stimulation,	
that	is,	lower	during	MA	stimulation	and	significantly	higher	during	
stimulation by SB 242084. The SB 242084 antagonist significantly 
increased stimulated food intake in all the WT treatment groups. The 
significant	increases	in	the	CFE	groups	and	less	increase	in	the	PLAC	
group suggest that CFE interacts with activating signaling through 
the	 5‐HT2c	 receptor.	 It	 therefore	 follows	 that	 CFE’s	 attenuation	
of food intake involves potential downstream α‐MSH	PVN	 signal‐
ing,	 though	 this	 would	 need	 further	 research	 (Zhou	 et	 al.,	 2005).	
The antagonist was expected to suppress all serotonin signaling 
TA B L E  1  Saline	comparison	of	food	and	water	intake	after	stimulants—2DG,	MA,	and	the	5HT2c	receptor	antagonist	SB	242084
Comparisons 
SAL
SAL 2DG MA SB 242054
Mean SD Mean SD p Mean SD p Mean SD p
FOOD 
Snord116del (g)
100CFE (n = 12) 1.21 0.27 0.78 0.37 <0.001** 1.00 0.23 0.02* 1.46 0.38 0.11
33CFE (n = 12) 1.47 0.23 0.98 0.29 <0.001** 1.05 0.37 0.003** 1.60 0.64 0.51
PLAC	(n = 12) 1.46 0.41 1.01 0.26 0.003** 0.94 0.31 0.003** 1.55 0.47 0.63
FOOD WT (g)
100CFE (n = 12) 0.81 0.27 1.19 0.18 <0.001** 0.78 0.37 0.14 1.61 0.61 <0.001**
33CFE (n = 12) 0.94 0.30 1.36 0.30 0.002** 0.98 0.29 0.55 1.79 0.7 <0.001**
PLAC	(n = 12) 0.91 0.39 1.56 0.67 0.008** 1.01 0.26 0.47 1.25 0.44 0.06
Note. Unpaired t	tests	with	the	mean	and	standard	deviation	(SD)	of	food	in	grams	(g)	ingested	over	4hrs	from	baseline,	in	the	Snord116del mouse model 
and	C57BL/6	wild	type	(WT)	strain.	Measurement	after	intraperitoneal	(i.p.)	injections	of	control	saline	(SAL)	or	stimulants:	2‐deoxy‐glucose	(2DG),	
(400mg/kg,	10mg	=	25g	mouse),	beta	–	mercaptoacetate	(MA)	(100mg/kg,	2.5mg	=	25g	mouse),	or	the	5‐HT2cR	antagonist	SB242804	(1.0mg/kg,	
025mg=	25g	mouse).	The	randomized	factors	were	treatment:	extract	of	Caralluma fimbriata (CFE) x 2 doses (100mg/kg/d & 33mg/kg) or placebo of 
maltodextrin/cabbage	leaf	(PLAC).	The	level	of	significance	is	reported	as	p	=	0.05*	and	p = 0.001**.
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through this receptor. Though there is no significant difference in 
the Snord116del	mouse	model’s	 comparisons	 (SAL	vs.	SB	242084),	
this	may	be	due	to	an	overall	functional	inactivity.	Clearly,	it	is	a	limi‐
tation of this study that this behavioral observation was not able to 
be tested by immunohistochemistry.
In	 the	 control	 SAL	 groups,	 it	 is	 important	 to	 address	 the	 ob‐
servation that the Snord116del mice ate more than the WT during 
the	4‐hr	food	 intake	tests.	This	result	was	consistent	with	the	hy‐
perphagic phenotype of the Snord116del mouse model charac‐
terizations	 in	 the	 literature	 (Qi	et	 al.,	2016);	 (Overstreet‐Wadiche,	
F I G U R E  1  Appetite	Stimulant	Histograms.	Figure	1	depicts	the	univariate	between‐subject	results	for	appetite	signaling	tests	with	
SAL—saline	control,	mean	and	SD—standard	deviation	of	food	ingested	in	grams	in	comparison	with	the	appetite	signaling	reagents	2DG—2‐
deoxyglucose,	MA—beta‐mercaptoacetate	or	the	5‐HT2c	antagonist	SB242804.	The	results	present	pairwise	comparisons	for	food	ingested	
over	four	hours,	with	significance	set	as	Pillai's	trace	Sig	value,	p = ≤0.05,	plus	t tests between three chronic treatment groups saline versus 
appetite signaling. The animal models were the Snord116del	(SNO)	and	wild‐type	(WT)	strains.	All	animals	were	ingesting	a	chronic	treatment	
of either CFE—Caralluma fimbriata	extract,	at	one	of	two	doses	100	mg/kg/d	or	33	mg/kg/d	or	PLAC—placebo	of	maltodextrin/cabbage	leaf	
[SNO: n	=	36;	WT:	n	=	36:	(100CFE/M:	n	=	6	and	F:	n	=	6;	33CFE/M:	n	=	6	and	F:	n	=	6;	and	PLAC/M:	n	=	6	and	F:	n	=	6)]
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Bensen,	&	Westbrook,	2006).	Also	notable	are	the	complexities	in	
reduced	food	intake	involving	administration	of	2DG	and	MA	in	the	
Snord116del	mice	(Table	1).	When	deprived	of	glucose,	the	natural	
homeostatic response in a mouse is to reduce the amount of en‐
ergy	 utilized	 and	 to	 consume	 food	 (Herzog,	 2012).	 However,	 the	
Snord116del animals demonstrated unexpected and distinct behav‐
ioral effects during stimulated glucose deprivation. The most com‐
mon observation was of a curled still posture as though the mice 
were	conserving	energy.	Further,	this	was	most	strongly	observed	
in the Snord116del	mice	ingesting	100CFE.	Overall,	this	behavioral	
observation may be due to the Snord116del mouse model’s lean phe‐
notype	and	is	consistent	with	another	report	of	lower	5‐hr	fasting	
glucose	levels	(Qi	et	al.,	2016).	Yet,	further	study	may	show	that	the	
Snord116del's conserving of energy is due to disrupted signaling 
specifically necessary for glucoprivic feeding and that CFE exagger‐
ates the attenuation of food intake related to glucose homeostasis. 
Further,	though	MA	stimulation	did	not	significantly	increase	food	
intake	 in	 the	WT	 groups,	 it	 did	 significantly	 lower	 food	 intake	 in	
all Snord116del	 groups	against	SAL.	Though	 it	 is	 unlikely	 that	 glu‐
coprivic or lipoprivic signals contribute to food intake during daily 
events	in	humans,	research	into	glucose	deprivation	or	β‐oxidation 
of fatty acids may be worth following through associated with both 
CFE and the SNORD116 deletion in humans.
The	SNO‐2DG	activation	of	NPY	neurones	as	indicated	by	c‐Fos	
and	NPY,	 in	 both	 the	CFE	 and	PLAC	groups,	was	 consistent	with	
the	 lower	 food	 intake.	 Regarding	 cell	 counts,	 it	 is	 apparent	 that	
2DG	stimulation	 resulted	 in	 lower	 c‐Fos	 and	NPY	 signaling	 in	 the	
SNO‐2DG	hypothalamus	in	both	ARC	and	PVN,	especially	in	com‐
parison	with	 the	higher	c‐Fos	and	NPY	dual‐labeled	counts	 in	 the	
WT‐2DG	groups.	Within	all	groups,	the	highest	c‐Fos	and	NPY	activ‐
ity	was	consistent	with	the	behavioral	food	intake	in	the	WTPLAC	
animals.	 In	 contrast,	 the	 SNOPLAC	group	had	 a	 lower	 number	 of	
activated	NPY	neurones	compared	to	the	Snord116del group treated 
with	CFE.	This	was	 in	response	to	both	2DG	and	the	control	SAL,	
even	though	the	SNOPLAC	group	ate	more	food.	This	is	not	as	con‐
sistent though it is possible that the strength of α‐MSH	activity	in	
the	ARC	may	have	counteracted	the	excitatory	activity	of	c‐Fos	and	
NPY.	Though	not	 significant,	 in	 all	 treatment	 groups	 c‐Fos	 and	α‐
MSH activity was strongest after CFE treatment (Table 2). Research 
is necessary to verify signaling downstream through α‐MSH	
F I G U R E  2   Immunohistochemistry	comparison	of	strain	c‐Fos	and	NPY	cell	population.	Colocalization	of	neuropeptide	and	activity:	color	
image	(purple)	c‐Fos—Fos‐like	early	gene	expression	(green);	NPY—neuropeptide	Y	and	c‐Fos	in	brain	slices	from	the	ARC—arcuate	nucleus	
of the hypothalamus in SNO (n	=	5)—representative	of	Snord116del mice and in WT (n	=	5)—wild‐type	control,	ingesting	chronic	treatment	
100CFE—Caralluma fimbriata	extract,	at	100	mg/kg/d	or	PLAC—placebo	200	mg	maltodextrin	and	50	mg	cabbage	leaf,	with	food	intake	
stimulant,	signaling	reagents,	2DG—2‐deoxyglucose,	induced	by	i.p.	injection	(400	mg/kg,	10	mg	=25	g	mouse),	in	comparison	with	the	
control	SAL—i.p.	injection	of	isotonic	saline
cSNO100CFE – 2DG c-Fos               c-Fos NPY Merge
(a) (b) (c)
c-Fos                                                          
not counted as α-MSH
c-Fos                                                       NPY c-Fos & NPY
c-Fos                                                          
50μm Scheme  
WT100CFE-2DG 
c-Fos                                 NPY      Merge                                              
c- Fos (d) NPY (e) c -Fos & NPY (f) f)    
c-Fos                                                   no NPY                                                c-Fos  only
c-Fos NPY NPY
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pathways linked with CFE’s proposed mechanism of activity via the 
5‐HT2c	 receptor.	 This	may	 involve	 studying	 the	 effect	 of	CFE	on	
SAL	scores	in	mice	with	the	5‐HT2c	receptor	knocked	out,	as	com‐
pared to WT mice.
Within	all	groups	and	conditions,	the	strongest	food	intake	activ‐
ity	was	in	the	WTPLAC	animals,	which	under	2DG	stimuli	was	con‐
sistent	with	the	increased	activity	of	NPY	neurones.	The	SNO‐2DG	
cell	counts	 in	both	the	CFE	and	PLAC	groups	confirmed	the	lower	
intake	in	food.	It	is	possible	that	2DG	stimulation	in	the	Snord116del 
mice	interrupted	the	NPY	activity	in	both	ARC	and	PVN,	especially	
in	comparison	with	the	higher	NPY	activity	observed	in	the	WT‐2DG	
groups.	Unexpectedly,	 the	 SNOPLAC	 groups	 had	 a	 lower	 number	
of	activated	c‐Fos	and	NPY	neurones	compared	to	the	Snord116del 
animals ingesting treatment CFE. Even though this difference was 
observed	in	both	2DG	and	the	control	SAL	groups,	the	strength	of	
the α‐MSH	activity	in	the	ARC	may	have	gone	some	way	to	explain	
the	 behavioral	 inhibition	 of	 the	 excitatory	 activity	 of	 NPY	 in	 the	
SNO100CFE group.
Our research will now investigate increased signaling of satiety 
through downstream CNS pathways due to CFE and most impor‐
tantly clinical trials research in humans with PWS—investigating the 
efficacy of CFE treatment—may ultimately need to involve incorpo‐
rating	dose	escalation	of	CFE	(Griggs,	Su,	et	al.,	2015).	Observations	
may	 include	5‐HT2c	receptor	 lymphocyte	collection,	 to	determine	
enhanced	 transcription,	 translation,	or	activity	of	 fully	 functioning	
5‐HT2c	receptors.
5  | CONCLUSION
The results of the experiments investigating CFE determined an 
involvement	 of	 serotonin	 via	 the	 5‐HT2cR	 in	 the	 inhibitory	 ef‐
fect of CFE on food appetite. This study also determined that 
CFE treatment alters food intake in the Snord116del	 animals,	
though hyperphagia is still present compared to the WT controls. 
Importantly,	 although	 glucoprivic	 and	 lipoprivic	 stimuli	 would	
be	 expected	 to	 increase	 food	 intake,	 in	 the	 Snord116del	 strain,	
the	administration	of	 reagents	2DG	and	MA	resulted	 in	 reduced	
stimulation of food intake. This was especially strong in the group 
ingesting	CFE,	compared	to	the	stimulated	feeding	in	the	WT	ani‐
mals. Immunohistochemical mapping of neuronal activation was 
consistent with the feeding behavior.
F I G U R E  3   Immunohistochemistry	comparison	of	strain	c‐Fos	and	α‐MSH	cell	population.	Colocalization	of	neuropeptide	and	activity:	
Color	image	(purple)	c‐Fos—Fos‐like	early	gene	expression	(red);	α‐MSH—alpha‐melanocyte‐stimulating	hormone;	and	C‐Fos	in	brain	slices	
from	the	ARC—arcuate	nucleus	of	the	hypothalamus	in	SNO	(n	=	5)—representative	of	Snord116del mice and in WT (n	=	5)—wild‐type	
control,	ingesting	chronic	treatment	100CFE—Caralluma fimbriata	extract,	at	100	mg/kg/d	or	PLAC—placebo	200	mg	maltodextrin	and	
50	mg	cabbage	leaf,	with	food	intake	stimulant,	signaling	reagents,	2DG—2‐deoxyglucose,	induced	by	i.p.	injection	(400	mg/kg,	10	mg	=25	g	
mouse),	in	comparison	with	the	control	SAL—i.p.	injection	of	isotonic	saline
SNO100CFE – 2DG c-Fos               c-Fos α-MSH                                            Merge
(a) (b)        (c)
c-Fos                                                          
not counted as α-MSH
c-Fos                                                        α-MSH                                                               c-Fos & α-MSH
c-Fos                                                          
50μm Scheme  
WT100CFE-2DG 
c-Fos                                 α-MSH                                             Merge                                              
c- Fos (d)                        α-MSH (e)                    c -Fos & α-MSH (f)                                         f)    
c-Fos                                                no α-MSH                                          c-Fos  only
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